Parkinson's disease (PD)-related phenotypes can vary among patients substantially,
including response to dopaminergic treatment in terms of efficacy and occurrence of adverse …

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by a
heterogeneous array of motor and non-motor features. Anti-PD drugs that are in use target …

Background Parkinson's disease (PD) is the second most common neurodegenerative
disease with a significant public health burden. It is characterized by the gradual …

Parkinson's disease (PD) is a condition with heterogeneous clinical manifestations that vary
in age at onset, rate of progression, disease course, severity, motor and non-motor …

Parkinson's disease (PD) is a chronic progressive neurodegenerative brain disorder
presenting with motor signs and symptoms, such as akinesia, rest tremor, rigidity, and later …

Parkinson's disease (PD) is unique among neurodegenerative disorders because a highly
effective pharmacological symptomatic treatment is available. The marked variability in drug …

Parkinson's disease (PD) is a debilitating, demoralizing and financially devastating condition
affecting 1% of population at the age of 60 years. Thus, very important issue to address is …

Introduction: There is a considerable inter-individual heterogeneity in clinical features,
disease course, and treatment response in Parkinson's disease (PD), which can be …

receptor DRD2 gene, the dopamine transporter (DAT) gene and µ1 opioid receptor
(OPRM1) gene. Motor fluctuations have been associated with a DRD2 gene polymorphism …

Recently, a lot of progress has been made in the identification of genetic biomarkers of drug
response. Efforts to define the role of genetic polymorphisms in optimizing pharmacotherapy …